
|Videos|May 18, 2017
Long-Term Strategies in Advanced HCC
Long-Term Strategies in Advanced HCC
Advertisement
May 2016
- A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively
April 2017
- Documented radiographic progression
- Therapy with regorafenib at 160mg was initiated
- Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5




















